Avastin Approved to Treat Ovarian Cancer
November 14, 2014 – Genentech’s Avastin® (bevacizumab) is now FDA-approved for an expanded indication to treat women with platinum-resistant, recurrent ovarian cancer. Avastin is an infused biologic drug known as an angiogenesis inhibitor; it helps prevent tumor blood vessel formation and is also approved for use in the treatment of colorectal cancer, glioblastoma, non-small cell lung cancer, renal cell carcinoma and cervical cancer.
FDA approval was based on a clinical trial that showed patients treated with Avastin plus chemotherapy reduced the risk of disease worsening by 62%, as compared to those treated with only chemotherapy (6.8 months versus 3.4 months). It is estimated that 22,000 women are diagnosed with ovarian cancer each year in the U.S.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Prices referenced are estimates based on available data and are subject to change at the time a claim is processed. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information purposes only. The reference to any medication above does not imply that the medication is covered by your plan.